Description

Cholinergic system dysfunction in Alzheimer's disease and current cholinesterase inhibitor therapies are illustrated, showing how acetylcholine deficiency contributes to cognitive decline.

More Figures from This Paper

Figure 1

Major pharmacotherapeutic targets in Alzheimer's disease are mapped, including amyloid-beta aggregation, tau hyperphosphorylation, neuroinflammation, and cholinergic dysfunction as key intervention points.

diagram

Figure 2

The amyloid cascade hypothesis and its therapeutic targets are illustrated, showing how beta-secretase and gamma-secretase inhibitors, along with anti-amyloid antibodies, aim to reduce pathological plaque formation.

diagram

Figure 3

Tau protein pathology and potential therapeutic interventions are depicted, including kinase inhibitors and immunotherapy approaches targeting neurofibrillary tangle formation in Alzheimer's disease.

diagram

Figure 4

Neuroinflammatory pathways in Alzheimer's disease and anti-inflammatory therapeutic targets are outlined, showing microglial activation, cytokine cascades, and potential points of pharmacological intervention.

diagram

Figure 5

Traditional medicinal plants investigated for Alzheimer's management are catalogued with their bioactive compounds and proposed neuroprotective mechanisms, including antioxidant and anti-inflammatory activities.

diagram

Figure 6

Diagram

720 × 380px · 193,3 Kio

Source Paper

Review of Pharmacotherapeutic Targets in Alzheimer's Disease and Its Management Using Traditional Medicinal Plants.

Degenerative neurological and neuromuscular disease (2024)

PMID: 38784601

DOI: 10.2147/DNND.S452009

Cite This Figure

![Figure 6: Cholinergic system dysfunction in Alzheimer's disease and current cholinesterase inhibitor therapies are illustrated, showing how acetylcholine deficiency contributes to cognitive decline.](https://pdfs.citedhealth.com/figures/38784601/599.png)

> Source: Prabhash Nath Tripathi et al. "Review of Pharmacotherapeutic Targets in Alzheimer's Disease and Its Management ." *Degenerative neurological and neuromuscular disease*, 2024. PMID: [38784601](https://pubmed.ncbi.nlm.nih.gov/38784601/)

<figure>
  <img src="https://pdfs.citedhealth.com/figures/38784601/599.png" alt="Cholinergic system dysfunction in Alzheimer's disease and current cholinesterase inhibitor therapies are illustrated, showing how acetylcholine deficiency contributes to cognitive decline." />
  <figcaption>Figure 6. Cholinergic system dysfunction in Alzheimer's disease and current cholinesterase inhibitor therapies are illustrated, showing how acetylcholine deficiency contributes to cognitive decline.<br>  Source: Prabhash Nath Tripathi et al. "Review of Pharmacotherapeutic Targets in Alzheimer's Disease and Its Management ." <em>Degenerative neurological and neuromuscular disease</em>, 2024. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/38784601/">38784601</a></figcaption>
</figure>